Will

@semodough Bronchiectasis is very difficult to treat. This $INSM drug appears to be the first advance in many years.

$INSM Truist $INSM - KOLs Share Contrasting Views On Brinsupri's Outlook: Key Takeaways From Our Calls -hosted two high-volume bronchiectasis KOLs to gather perspectives on Brinsupri’s current role in clinical practice & expectations for future uptake. Notably, the KOLs expressed somewhat divergent views, which we believe broadly reflect the prevailing bull vs bear debate on the Street.Our take: Our doc feedback to-date has skewed modestly positive, though we acknowledge the limited sample size. Broadly, it remains early to draw definitive conclusions on Brinsupri’s impact, as physicians need more follow-up time to assess for improvements on exacerbation rates & lung function

$BX today announced a joint venture with $GOOGL to create a new U.S.-based company that will offer efficient data center capacity, operations, networking, and Google Cloud's Tensor Processing Units (TPUs) as a compute-as-a-service offering. www3.blackstone.com/webmail/103723…

S&P +0.1% last wk, masks the troubles under the surface with oil +10% to $105 & 2/30 yr bond yields +18 bps. I said last wk in multiple interviews that either oil/ylds are wrong or the stock mkt is. Much like on Friday, I am expecting more convergence this wk. Both April CPI & PPI came in higher than expected last week stoking the fears that the rising oil prices from the Iran war which started in late February is now impacting inflation. In addition, there was some troubling developments in the semiconductor sector which has spearheaded the recent 18% rally in the S&P with a 69% gain in the SOX index from March 30th to Thursday May 14th. The Korean Kospi, which had been up 89% ytd through Thursday led by memory manufacturers Samsung Electronics +143% and Hynix +201% had its biggest intraday spread in history on Friday which triggered a temporary trading halt. The Kospi from an intra-day high of +0.8% finished down 6.1% with Samsung/Hynix closing down 6.6%/5.9%. This week, we will get some important earnings releases from $TGT on Wednesday and $WMT on Thursday with combined sales of ~$850B on how the consumer is handling the increase in gas prices. Most analysts are expecting solid results. This would match statements from the credit card companies and larger banks which indicated a resilient consumer when they reported. However, $MCD in reporting their quarterly earnings in early May, talked about a slowdown they were seeing in the lower-end consumer $NVDA results on Wednesday will speak to the health of the AI trade. While I expect another beat & raise quarter, the stock has declined each of the past 3 quarters in reaction to earnings the next day. The 5.5% decline in reaction to their January quarter results where revenues were 3% above consensus and they guided 7% above for the next quarter was particularly noteworthy. The stock was also up 43% from 3/30-5/14. This is a very different risk vs reward than on April 5th when I wrote "$NVDA and $GOOGL remain my favorite ways to play agentic AI while the server microprocessor vendors are key new beneficiaries from the increase in orchestration needed." As an aside, Google was up 47% from 3/30-5/14. From a bigger picture basis, the number one thing I am focused on when investing is risk vs reward. I posted on X on March 31st “History May not Repeat Itself but it Often Does Rhyme” comparing 2026 to 97/98 where macro scares caused the S&P to have intra-year declines of 11% and 19% but finished the years up 31% and 27%. I also mentioned again the benefits of Agentic AI “So names like $INTC and $AMD should benefit.” End of March was a great risk vs reward for investing. As I stated in interviews last week, however, the risk versus reward over the short-term is now very different. The S&P bounced 18% from March 30th through Thursday May 14th led by the Semiconductor Index that surged 69% but: 1) oil has risen to $105 versus $84 on April 17th when a resolution seemed more likely and versus the mid-$60s before the Iran war started 2) bond yields are at new highs for the yr with the 30 yr firmly above 5% and 2 yr firmly above 4% and up over 20 bps and 35 bps since April 17th 3) recent data seems to indicate that rising oil prices is seeping into inflation Until oil and bond yields look like they are going to come back down for good reasons versus bad ones like demand destruction, I have little interest in getting aggressive on stocks. This is why on my podcast with @WilfredFrost on Tuesday I said “hold more cash.” x.com/DanielTNiles/s… Longer-term, I still believe two of the most powerful forces driving the market remain intact 1) AI capex now up ~70% vs ~30% at the start of the year driven by the advent of Agentic AI in early 2026 2) the desire for easy money policies by new Fed Chairman Kevin Warsh though his hands are seemingly tied at the moment by rising inflation metrics Mid-term elections are also coming up in November and if oil prices are not down by then, historical precedence says the incumbent party is going to suffer significant losses. This is a powerful incentive to resolve the Iran situation sooner rather than later. In summary, in the near-term the risk vs reward for stocks seems poor unlike in late March. My key to when it makes sense to get more aggressive again rests with oil and bond yields given 10 out of the last 12 recession were preceded by a sustained surge in oil prices.

$NPCE : Price target to $20.00. Doesn’t include Idiopathic Generalized Epilepsy contribution.

$EDAP Focal One Gaining Traction In The Treatment Of Prostate Cancer.

$HTFL : Price target $37 from an influential analyst.

$HTFL : Firing on all cylinders. Technology reshapes the diagnosis and treatment approach to coronary artery disease. Coronary artery tree in 3D!

$HTFL Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance. “We continue to extend our leadership position, becoming the AI operating system of record for the detection, diagnosis, management, and treatment planning of CAD”. ir.heartflow.com/news-releases/…

$DOCS: Is getting crushed after issuing a terrible forecast for its fiscal 2027. Shares of the so-called LinkedIn for doctors are down over 23% this morning. Revenue and adjusted operating profitability were both light versus consensus. Doctors “social media” site questionable.

$MGTX Reports First Quarter 2026 Financial and Operational Results: A lot good things going on at MGTX! investors.meiragtx.com/news-releases/…

@drsprs Always found it quite useless. Touted as the doctor’s social media.

Doximity dying off. $DOCS DOA.

This is absolutely insane. President Trump is currently flying to China with all of the following people to request "deals" with China's President Xi: 1. Elon Musk, Tesla and SpaceX CEO 2. Jensen Huang, Nvidia CEO 3. Tim Cook, Apple CEO 4. Larry Fink, BlackRock CEO 5. Stephen Schwarzman, Blackstone CEO 6. Kelly Ortberg, Boeing CEO 7. Brian Sikes, Cargill CEO 8. Jane Fraser, Citigroup CEO 9. Larry Culp, General Electric CEO 10. David Solomon, Goldman Sachs CEO 11. Sanjay Mehrotra, Micron CEO 12. Cristiano Amon, Qualcomm CEO President Trump also says there are "many other" CEOs joining him on the trip who have not yet been disclosed. Never in history has such a trip even remotely near this scale and caliber occurred. This Trump-Xi meeting is far bigger than most realize.

@Colecalciferol1 You have no idea what you are talking about regarding Dr. Rasmussen and his role with this technology and its ultimate implications for vascular surgery.

$HUMA - Humacyte Q1 figures, light and shadow What Fintwit has known for 2 weeks has now been confirmed: Headcount reduction by 25% (which is higher than what we estimated: 10-15%) - Good layoff, considering the cash burn faced. These are hard cuts, but absolutely necessary for the simple survival of the company. Sales quantity remains devastating, but at least management now acknowledges the issue. Depending on price point, Q1 saw sales of 25-30 Symvess, not sending any signal of sales taking off or of increasing market penetration. Frustrating: Management is pushing forward with CABG trials. This will generate sales at the earliest in 4-5 years, potentially even longer. Management needs to pause or stop these trials. The company will die if it keeps following too many programs - at the new cash burn they have run way for 6 months max The hires are good, but Rasmussen specifically is a cosmetic hire that could have been done 1-2 years ago. Good experience with Mayo and DoD, but don’t be mistaken: Rasmussen is a doctor ultimately, no management role or expected influence on Mayo spending. V012 got even more binary.

$KURA : Ziftomenib – Frontline AML: Present updated results for ziftomenib / 7+3 combination in frontline NPM1-m/KMT2A-r AML (KOMET-007) in an oral presentation at the European Hematology Association (EHA) 2026 Congress in June 2026. Frontline is the prize.

$NPCE raises guidance and reiterates anticipated FDA approval of idiopathic generalized epilepsy indication for “mid-year”. Management emphasizes guidance does not include any revenues from the IGE indication. TAM represents 40% of drug resistant epileptics.

$HUMA Appoints Dr. Todd E. Rasmussen as Chief Surgical Officer. This is a very good appointment! “Mayo Clinic has a financial interest in Humacyte. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care”. humacyte.gcs-web.com/news-releases/…

$XENE : Azetukalner setting up to be best in class ASM in Focal Onset Seizures & other indications.

$ALKS Extended release once nightly Oxybate meets all endpoints in phase 3 IH trial. “The data from REVITALYZ demonstrate the potential utility of once-nightly LUMRYZ as an effective treatment for excessive daytime sleepiness associated with IH”. share.google/omBv3KsSdwadw8…

$MBX Bioscience long acting molecules may have a place in hypoparathyroidism & obesity.

Opposition forming against radiologist nominee for surgeon general Ross University School of Medicine in Portsmouth, Dominica, with a Doctor of Medicine. radiologybusiness.com/topics/healthc…